ID: ALA87964

Max Phase: Preclinical

Molecular Formula: C24H29N7O

Molecular Weight: 431.54

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CCCCc1nn(C(C)CC)c(=O)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1

Standard InChI:  InChI=1S/C24H29N7O/c1-4-6-11-22-27-31(17(3)5-2)24(32)30(22)16-18-12-14-19(15-13-18)20-9-7-8-10-21(20)23-25-28-29-26-23/h7-10,12-15,17H,4-6,11,16H2,1-3H3,(H,25,26,28,29)

Standard InChI Key:  HZRZZXFVGPKWLK-UHFFFAOYSA-N

Associated Targets(Human)

Angiotensin II receptor 1039 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Type-1B angiotensin II receptor 525 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Angiotensin II type 1a (AT-1a) receptor 1700 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Angiotensin II receptor (AT-1) type-1 1480 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 431.54Molecular Weight (Monoisotopic): 431.2434AlogP: 4.25#Rotatable Bonds: 9
Polar Surface Area: 94.28Molecular Species: ACIDHBA: 7HBD: 1
#RO5 Violations: 0HBA (Lipinski): 8HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: 5.85CX Basic pKa: CX LogP: 6.71CX LogD: 5.45
Aromatic Rings: 4Heavy Atoms: 32QED Weighted: 0.43Np Likeness Score: -1.11

References

1. Huang HC, Reitz DB, Chamberlain TS, Olins GM, Corpus VM, McMahon EG, Palomo MA, Koepke JP, Smits GJ, McGraw DE..  (1993)  Synthesis and structure-activity relationships of nonpeptide, potent triazolone-based angiotensin II receptor antagonists.,  36  (15): [PMID:8340920] [10.1021/jm00067a015]
2. Chang LL, Ashton WT, Flanagan KL, Strelitz RA, MacCoss M, Greenlee WJ, Chang RS, Lotti VJ, Faust KA, Chen TB..  (1993)  Triazolinones as nonpeptide angiotensin II antagonists. 1. Synthesis and evaluation of potent 2,4,5-trisubstituted triazolinones.,  36  (17): [PMID:8355255] [10.1021/jm00069a015]
3. Parate A, Chaturvedi SC.  (2012)  Predicting 3H-1,2,4-triazolinones as angiotensin II receptor antagonists: 2D and 3D QSAR by kNN-molecular field analysis approach,  21  (7): [10.1007/s00044-011-9622-4]
4. Parate A, Chaturvedi SC.  (2010)  Structural insights for 3H-1, -2, -4 triazolinones as angiotensin II receptor antagonists using QSAR techniques,  19  (4): [10.1007/s00044-009-9197-5]

Source